Clinical significance of intensity-modulated radiotherapy (IMRT) to the distant metastatic lymph nodes for metastatic cervical cancer.
Cervical cancer
Distant metastatic lymph nodes
Intensity-modulated radiotherapy
Survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
20 Sep 2024
20 Sep 2024
Historique:
received:
24
04
2024
accepted:
03
09
2024
medline:
21
9
2024
pubmed:
21
9
2024
entrez:
20
9
2024
Statut:
epublish
Résumé
To retrospectively explore the clinical significance of radiotherapy to the distant metastatic lymph nodes (cervical/ clavicular/ mediastinal et al.) in metastatic cervical cancer. Hereinto, these cervicothoracic lymph nodes were metastasized from IB1-IVA (initial stage at first treatment), and IVB initially had metastatic disease in these areas at diagnosis. Metastatic cervical cancer only with the distant cervicothoracic metastatic lymph nodes (cervical/ clavicular/ mediastinal et al.), without distant parenchymal organs metastasis such as lung, liver, bone, and peritoneum, were enrolled in the analysis. These patients were classified into IB1-IVA and IVB based on their initial stage of first treatment. All patients received IMRT for the distant metastatic lymph nodes. The progression-free survival (PFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Overall, the median PFS was 9 months, and the median OS was 27 months. The subgroup analysis showed that for IB1-IVA, the median PFS was 11 months, and the median OS was 30.5 months. For IVB, the median PFS was 8 months, and the median OS was 16 months. Radiotherapy is beneficial to the distant metastatic lymph nodes (cervical/ clavicular/ mediastinal et al.), and could effectively bring the longer PFS and OS for metastatic cervical cancer.
Identifiants
pubmed: 39304814
doi: 10.1186/s12885-024-12895-2
pii: 10.1186/s12885-024-12895-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1170Informations de copyright
© 2024. The Author(s).
Références
Alix-Panabières C, Pantel K. Clinical applications of circulating Tumor cells and circulating tumor DNA as Liquid Biopsy. Cancer Discov. 2016;6(5):479–91.
doi: 10.1158/2159-8290.CD-15-1483
pubmed: 26969689
Sung H, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
doi: 10.3322/caac.21660
pubmed: 33538338
Guo M, Xu J, Du J. Trends in cervical cancer mortality in China from 1989 to 2018: an age-period-cohort study and joinpoint analysis. BMC Public Health. 2021;21(1):1329.
doi: 10.1186/s12889-021-11401-8
pubmed: 34229639
pmcid: 8259057
Feng CH, et al. Immunotherapy with Radiotherapy and Chemoradiotherapy for Cervical Cancer. Semin Radiat Oncol. 2020;30(4):273–80.
doi: 10.1016/j.semradonc.2020.05.003
pubmed: 32828383
Pfaendler KS, Tewari KS. Changing paradigms in the systemic treatment of advanced cervical cancer. Am J Obstet Gynecol. 2016;214(1):22–30.
doi: 10.1016/j.ajog.2015.07.022
pubmed: 26212178
Tewari KS, et al. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014;370(8):734–43.
doi: 10.1056/NEJMoa1309748
pubmed: 24552320
pmcid: 4010094
Kobayashi R, et al. Details of recurrence sites after definitive radiation therapy for cervical cancer. J Gynecol Oncol. 2016;27(2):e16.
doi: 10.3802/jgo.2016.27.e16
pubmed: 26463432
Kozaki M, et al. Therapy-free interval has prognostic value in patients with recurrent cervical cancer treated with chemotherapy following definitive concurrent chemoradiotherapy. Arch Gynecol Obstet. 2017;296(5):997–1003.
doi: 10.1007/s00404-017-4520-8
pubmed: 28884382
Koh WJ, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(1):64–84.
doi: 10.6004/jnccn.2019.0001
pubmed: 30659131
Cibula D, et al. The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with cervical cancer. Radiother Oncol. 2018;127(3):404–16.
doi: 10.1016/j.radonc.2018.03.003
pubmed: 29728273
Leath CA 3rd and, Straughn JM Jr. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials. Gynecol Oncol. 2013;129(1):251–7.
doi: 10.1016/j.ygyno.2012.12.035
pubmed: 23280089
Mazeron R, et al. Adaptive 3D image-guided brachytherapy: a strong argument in the debate on systematic radical hysterectomy for locally advanced cervical cancer. Oncologist. 2013;18(4):415–22.
doi: 10.1634/theoncologist.2012-0367
pubmed: 23568003
pmcid: 3639528
Li H, Wu X, Cheng X. Advances in diagnosis and treatment of metastatic cervical cancer. J Gynecol Oncol. 2016;27(4):e43.
doi: 10.3802/jgo.2016.27.e43
pubmed: 27171673
pmcid: 4864519
Shelley CE, et al. Adaptive Radiotherapy in the management of Cervical Cancer: review of strategies and clinical implementation. Clin Oncol (R Coll Radiol). 2021;33(9):579–90.
doi: 10.1016/j.clon.2021.06.007
pubmed: 34247890
Singh AK, et al. Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence. Int J Radiat Oncol Biol Phys. 2005;61(2):450–5.
doi: 10.1016/j.ijrobp.2004.06.207
pubmed: 15667966
Small W Jr., et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys. 2008;71(2):428–34.
doi: 10.1016/j.ijrobp.2007.09.042
pubmed: 18037584
Bonomi P, et al. Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1985;3(8):1079–85.
doi: 10.1200/JCO.1985.3.8.1079
pubmed: 3894589
van Meir H, et al. The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy. Anticancer Agents Med Chem. 2014;14(2):190–203.
doi: 10.2174/18715206113136660372
pubmed: 24237223
Ferrari F, Giannini A. Approaches to prevention of gynecological malignancies. BMC Womens Health. 2024;24(1):254.
doi: 10.1186/s12905-024-03100-4
pubmed: 38654319
pmcid: 11036672
Peiretti M, et al. Management of recurrent cervical cancer: a review of the literature. Surg Oncol. 2012;21(2):e59–66.
doi: 10.1016/j.suronc.2011.12.008
pubmed: 22244884
Okazawa-Sakai M, et al. Predictors of distant relapse in patients with FIGO stage IIB-IVA cervical cancer treated with definitive radiotherapy. J Obstet Gynaecol Res. 2017;43(11):1743–50.
doi: 10.1111/jog.13446
pubmed: 28816403
Monk BJ, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27(28):4649–55.
doi: 10.1200/JCO.2009.21.8909
pubmed: 19720909
pmcid: 2754911
Moore DH, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22(15):3113–9.
doi: 10.1200/JCO.2004.04.170
pubmed: 15284262
Fiorica JV, et al. A phase II evaluation of weekly topotecan as a single agent second line therapy in persistent or recurrent carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;115(2):285–9.
doi: 10.1016/j.ygyno.2009.07.024
pubmed: 19726073
Tewari KS, et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654–63.
doi: 10.1016/S0140-6736(17)31607-0
pubmed: 28756902
pmcid: 5714293
Monk BJ, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2009;27(7):1069–74.
doi: 10.1200/JCO.2008.18.9043
pubmed: 19139430
pmcid: 2667811
Colombo N, et al. Pembrolizumab for Persistent, recurrent, or metastatic cervical Cancer. N Engl J Med. 2021;385(20):1856–67.
doi: 10.1056/NEJMoa2112435
pubmed: 34534429
D’Oria O, et al. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature. Expert Opin Pharmacother. 2024;25(1):55–65.
doi: 10.1080/14656566.2023.2298329
pubmed: 38159033
Coleman RL, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021;22(5):609–19.
doi: 10.1016/S1470-2045(21)00056-5
pubmed: 33845034